Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

NCT00128232 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: Octreotide LAR

Sponsor

Novartis